Gilead Sciences Inc. (NASDAQ:GILD) has a beta value of 0.42 and has seen 4.76 million shares traded in the last trading session. The company, currently valued at $106.16B, closed the last trade at $84.02 per share which meant it gained $0.79 on the day or 0.95% during that session. The GILD stock price is -6.81% off its 52-week high price of $89.74 and 31.96% above the 52-week low of $57.17. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.93 million shares traded. The 3-month trading volume is 8.04 million shares.
The consensus among analysts is that Gilead Sciences Inc. (GILD) is an Overweight stock at the moment, with a recommendation rating of 2.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 18 out of 30 have rated it as a Hold, with 12 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is $1.39.
Gilead Sciences Inc. (NASDAQ:GILD) trade information
Sporting 0.95% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on Tuesday, 01/24/23 when the GILD stock price touched $84.02 or saw a rise of 1.3%. Year-to-date, Gilead Sciences Inc. shares have moved -2.13%, while the 5-day performance has seen it change -1.63%. Over the past 30 days, the shares of Gilead Sciences Inc. (NASDAQ:GILD) have changed -1.47%. Short interest in the company has seen 16.47 million shares shorted with days to cover at 2.19.
Wall Street analysts have a consensus price target for the stock at $87.40, which means that the shares’ value could jump 3.87% from current levels. The projected low price target is $69.00 while the price target rests at a high of $111.00. In that case, then, we find that the current price level is -32.11% off the targeted high while a plunge would see the stock lose 17.88% from current levels.
Gilead Sciences Inc. (GILD) estimates and forecasts
Figures show that Gilead Sciences Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 38.30% over the past 6 months, with this year growth rate of -2.75%, compared to 4.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 101.40% and -24.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be -7.50%.
20 analysts offering their estimates for the company have set an average revenue estimate of $6.35 billion for the current quarter. 8 have an estimated revenue figure of $5.92 billion for the next quarter concluding in Mar 2023. Year-ago sales stood $7.24 billion and $6.28 billion respectively for this quarter and the next, and analysts expect sales will shrink by -12.40% for the current quarter and -5.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -13.10% over the past 5 years. Earnings growth for 2023 is a modest -2.30% while over the next 5 years, the company’s earnings are expected to increase by 2.00%.
Gilead Sciences Inc. is expected to release its next earnings report between January 30 and February 03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 2.92 at a share yield of 3.48%. The company’s dividend yield has gone up over the past 12 months.
Gilead Sciences Inc. (NASDAQ:GILD)’s Major holders
Insiders own 0.09% of the company shares, while shares held by institutions stand at 82.11% with a share float percentage of 82.18%. Investors are also buoyed by the number of investors in a company, with Gilead Sciences Inc. having a total of 2,203 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 126.94 million shares worth more than $7.85 billion. As of Jun 29, 2022, Blackrock Inc. held 10.13% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 110.4 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $6.82 billion and represent 8.81% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. As of Jun 29, 2022, the former fund manager holds about 2.95% shares in the company for having 36.93 million shares of worth $2.28 billion while later fund manager owns 27.76 million shares of worth $1.72 billion as of Jun 29, 2022, which makes it owner of about 2.22% of company’s outstanding stock.